# US 2020/0262889 A1 · Succinate-binding polypeptides and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0262889 A1
- Document ID: US20200262889A1
- Status: Published application
- Kind: A1
- Application number: 16/647,945
- Filed: 2018-09-18
- Published: 2020-08-20
- Earliest claimed: 2017-09-18
- Assignees: B.G. Negev Technologies and Applications Ltd., At Ben-Gurion University
- Applicants: B.G. Negev Technologies and Applications Ltd., At Ben-Gurion University
- Inventors: Ehud OHANA
- Web page: https://patentgrep.com/patent/US20200262889A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/12: Antihypertensives
- A61P 13/04: for urolithiasis
- C07K 14/47: from mammals
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/41: containing a Myc-tag
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/7095: Inflammation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Polypeptides comprising an amino acid sequence of Slc26a6 or IRBIT comprising a mutation that increases NaDC-1 binding, stability of the polypeptide, stability of NaDC-1 complex or a combination thereof are provided. Polypeptides comprising an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), comprising a mutation that increases succinate binding, stability of the polypeptide, stability of the mutSUCNR1-succinate complex or combinations thereof are also provided. Compositions comprising the polypeptides, nucleic acid molecules and vectors encoding the polypeptides, and methods of use of the polypeptides or compositions, specifically for treating succinate-associate diseases and conditions are also provided.

## Claims

### Claim 1

A method of treating or preventing a succinate-associated disease or condition in a subject in need thereof, the method comprising decreasing serum succinate levels in said subject, thereby treating or preventing a succinate-associated disease or condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein said succinate-associated disease or condition is selected from inflammatory bowel disease (IBD), urolithiasis, rheumatoid arthritis, cardiac hypertrophy, inflammation, kidney stones and hypertension.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein said IBD is selected from any one of: colitis, ulcerative colitis, Crohn's disease, and Bechet's disease.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein said decreasing serum succinate levels comprises administering succinate receptor 1 (SUCNR1) or a fragment, derivative, analog or mutant thereof, capable of binding succinate.

### Claim 8 (depends on 1)

The method of claim 1, wherein said decreasing serum succinate levels comprises decreasing solute carrier family 13 member 2 (NaDC-1) transport of succinate.

### Claim 9 (depends on 8)

The method of claim 8, wherein decreasing NaDC-1 transport of succinate comprises increasing binding of NaDC-1 to solute carrier family 26 member 6 (Slc26a6), IP3 receptor-binding protein released with IP3 (IRBIT) or both.

### Claim 10 (depends on 9)

The method of claim 9, wherein increasing binding to Slc26a6 comprises increasing electrostatic interaction between a STAS domain of Slc26a6 and a H4c domain of NaDC-1.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein said increasing binding of NaDC-1 to Slc26a6, IRBIT or both comprises administering to said subject a polypeptide comprising an amino acid sequence of:
a. a Slc26a6 STAS domain, or a fragment, derivative or analog thereof, capable of binding NaDC-1, and comprising glutamic acid 613 or aspartic acid 637; or
b. IRBIT or a fragment, derivative or analog thereof capable of binding NaDC-1.

### Claim 13 (depends on 12)

The method of claim 12, wherein said polypeptide comprises an amino acid sequence of a mutant Slc26a6 (mutSlc26a6) or mutant IRBIT (mutIRBIT), said mutSlc26a6 or mutIRBIT comprising at least one mutation which increases binding of said polypeptide to NaDC-1 as compared to a non-mutant Slc26a6 or IRBIT, increases stability of said polypeptide as compared to a non-mutant Slc26a6 or IRBIT, increases stability of a mutSlc26a6-NaDC-1 complex or a mutIRBIT-NaDC-1 complex as compared to a non-mutant Slc26a6-NaDC-1 complex or a non-mutant IRBIT-NaDC-1 complex, or any combination thereof.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 8)

The method of claim 8, wherein said NaDC-1 comprises the amino acid sequence provided in SEQ ID NO: 5 or SEQ ID NO: 6 and said at least one mutation increases binding to lysine 107, arginine 108, or both of SEQ ID NO: 5 or lysine 156, arginine 157, or both of SEQ ID NO: 6.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

A polypeptide comprising
a. an amino acid sequence of a mutant Slc26a6 (mutSlc26a6) or mutant IP(3)R binding protein released with IP(3) (mutIRBIT), said mutSlc26a6 or mutIRBIT comprising at least one mutation which:
i. increases binding of said polypeptide to NaDC-1 as compared to a non-mutant Slc26a6 or IRBIT,
ii. increases stability of said polypeptide as compared to a non-mutant Slc26a6 or IRBIT,
iii. increases stability of a mutSlc26a6-NaDC-1 complex or a mutIRBIT-NaDC-1 complex as compared to a non-mutant Slc26a6-NaDC-1 complex or a non-mutant IRBIT-NaDC-1 complex, or
iv. any combination thereof;
b. an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), said mutSUCNR1 comprising at least one mutation which:
i. increases binding of said polypeptide to succinate as compared to a non-mutant SUCNR1,
ii. increases stability of said polypeptide as compared to a non-mutant SUCNR1,
iii. increases stability of a mutSUCNR1-succinate complex as compared to a non-mutant SUCNR1-succinate complex, or
iv. any combination thereof.

### Claim 21 (depends on 20)

The polypeptide of claim 20, wherein said at least one mutation increases negative charge in the Slc26a6-STAS domain.

### Claim 22

(canceled)

### Claim 23 (depends on 20)

The polypeptide of claim 20, wherein said at least one mutation of Slc26a6 is mutation of glutamic acid 613 of SEQ ID NO: 1 or aspartic acid 637 of SEQ ID NO: 2.

### Claim 24 (depends on 20)

The polypeptide of claim 20, wherein said at least one mutation is within the IRBIT PEST domain or PDZ-binding domain.

### Claim 25

(canceled)

### Claim 26 (depends on 20)

The polypeptide of claim 20, wherein an amino acid sequence of SUCNR1 is SEQ ID NO: 7, and wherein said at least one mutation is selected from the group consisting of: Leucine 191, Threonine 192, Glycine 195, Isoleucine 110, Phenylalanine 241, Methionine 203, Valine 238, Tyrosine 207, Arginine 120, Arginine 281, Phenylalanine 285, Asparagine 287, Tyrosine 295, or any combination thereof.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 20)

A nucleic acid molecule coding for the polypeptides of claim 20.

### Claim 31

(canceled)

### Claim 32 (depends on 20)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or adjuvant and the polypeptide of claim 20.

### Claim 33

(canceled)

### Claim 34

A method of increasing succinate reabsorption from urine in a subject in need thereof, the method comprising at least one of:
a. inhibiting interaction between NaDC-1 and IRBIT in said subject; and
b. inhibiting electrostatic interaction between the STAS domain of Slc26a6 and the H4c domain of NaDC-1,
thereby increasing succinate reabsorption in a subject in need thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein said inhibiting electrostatic interaction comprises blocking interaction of: (a) E613 or D637 of Slc26a6 with the H4c domain of NaDC-1, (b) K107, R108, K156 and/or R157 of NaDC-1 with the STAS domain of Slc26a6; or a combination of (a) and (b).

### Claim 36

(canceled)

### Claim 37 (depends on 34)

The method of claim 34, wherein blocking interaction comprises mutation of at least one of amino acids E613 and D637 of Slc26a6, and K107, R108, K156 and R157 of NaDC-1.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)
